<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <meta name="generator" content="pandoc">
  <meta name="author" content="Dr Carl Reynolds">
  <title>Work-related Interstitial Lung Disease: Beyond pneumoconiosis</title>
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
  <link rel="stylesheet" href="reveal.js/css/reveal.css">
  <style type="text/css">code{white-space: pre;}</style>
  <link rel="stylesheet" href="reveal.js/css/theme/black.css" id="theme">
  <!-- Printing and PDF exports -->
  <script>
    var link = document.createElement( 'link' );
    link.rel = 'stylesheet';
    link.type = 'text/css';
    link.href = window.location.search.match( /print-pdf/gi ) ? 'reveal.js/css/print/pdf.css' : 'reveal.js/css/print/paper.css';
    document.getElementsByTagName( 'head' )[0].appendChild( link );
  </script>
  <!--[if lt IE 9]>
  <script src="reveal.js/lib/js/html5shiv.js"></script>
  <![endif]-->
</head>
<body>
  <div class="reveal">
    <div class="slides">

<section>
  <h1 class="title">Work-related Interstitial Lung Disease: Beyond pneumoconiosis</h1>
  <h2 class="author">Dr Carl Reynolds</h2>
</section>

<section id="i-have-nothing-to-disclose" class="slide level2">
<h1>I have nothing to disclose</h1>
</section>
<section><section id="beyond-pneumoconiosis" class="titleslide slide level1"><h1>Beyond pneumoconiosis?</h1></section><section id="section" class="slide level2">
<h1></h1>
<figure>
<img src="images/KellingleyCollieryCloses2015.jpg" alt="Kellingley colliery workers" /><figcaption>Kellingley colliery workers</figcaption>
</figure>
</section><section id="section-1" class="slide level2">
<h1></h1>
<figure>
<img src="images/Pneumoconniosis.jpg" alt="HSE Pneumoconiosis figures" /><figcaption>HSE Pneumoconiosis figures</figcaption>
</figure>
</section><section id="section-2" class="slide level2">
<h1></h1>
<figure>
<img src="images/UndergroundCoalMiners.jpg" alt="Prevalence of progressive massive fibrosis in underground coal miners with 25 years of more exposure in three states of the USA (1)" /><figcaption>Prevalence of progressive massive fibrosis in underground coal miners with 25 years of more exposure in three states of the USA (1)</figcaption>
</figure>
</section></section>
<section><section id="what-is-work-related-ild" class="titleslide slide level1"><h1>What is work-related ILD?</h1></section><section id="definitions" class="slide level2">
<h1>Definitions</h1>
</section><section id="work-related-doesnt-mean-occupational" class="slide level2">
<h1>work-related doesn't mean occupational</h1>
</section><section id="section-3" class="slide level2">
<h1></h1>
<ul>
<li>occupational diseases are primarily caused by exposure to risk factors arising from work</li>
<li>work-related diseases have multiple causes; factors in workplace may play a role (WHO 2017)</li>
</ul>
</section><section id="diffuse-parenchymal-lung-disease-is-confusing" class="slide level2">
<h1>diffuse parenchymal lung disease is confusing</h1>
</section><section id="section-4" class="slide level2">
<h1></h1>
<ul>
<li>ILD or DPLD</li>
<li>heterogeneous group of disorders characterised by inflammation and fibrosis of the interstitium</li>
<li>interstitium refers to tissue between the pulmonary alveoli and the bloodstream</li>
<li>in practice disease can also involve airway</li>
</ul>
</section><section id="section-5" class="slide level2">
<h1></h1>
<figure>
<img src="images/Classific_diffuse_lung_dz.gif" alt="An ILD Taxonomy (7)" style="width:65.0%" /><figcaption>An ILD Taxonomy (7)</figcaption>
</figure>
</section><section id="section-6" class="slide level2">
<h1></h1>
<figure>
<img src="images/ILDCTBMJ.jpg" alt="CT appearance ILD (5)" style="width:65.0%" /><figcaption>CT appearance ILD (5)</figcaption>
</figure>
</section><section id="lung-physiology-and-interstitial-exposures" class="slide level2">
<h1>lung physiology and interstitial exposures</h1>
</section><section id="section-7" class="slide level2">
<h1></h1>
<ul>
<li>Diffusion of gases across blood-gas barrier is passive and governed by Fick's Law.</li>
</ul>
</section><section id="section-8" class="slide level2">
<h1></h1>
<figure>
<img src="images/Weibelmodel.jpg" alt="Weibel model" style="width:50.0%" /><figcaption>Weibel model</figcaption>
</figure>
</section><section id="section-9" class="slide level2">
<h1></h1>
<blockquote>
<p>Vgas (diffusing) is proportional to Area/Thickness * D(diffusion constant) * (P1 - P2)</p>
</blockquote>
<p>D = solubility / root of the molecular weight of the gas</p>
</section><section id="section-10" class="slide level2">
<h1></h1>
<figure>
<img src="images/Bloodgasbarrier.jpg" alt="Blood gas barrier" style="width:65.0%" /><figcaption>Blood gas barrier</figcaption>
</figure>
</section><section id="section-11" class="slide level2">
<h1></h1>
<ul>
<li>2μm across (for ref sheet of paper is 50μm, 1/20th of a mm or 0.05mm). (17)</li>
<li>25x thinner than that. 300 million alveolii.</li>
<li>Each alveoli is 0.0042mm^3 (a grain of sand is 0.06mm^3, so an alveoli is about 14 times smaller).(16) Surface area of a tennis court.</li>
<li>basic tripartate layout highly conserved throughout evolutionary history (alveolar epithelium, ECM, capillary endothelium, seen American lungfish arising some 400 million years ago) (18)</li>
</ul>
</section><section id="section-12" class="slide level2">
<h1></h1>
<blockquote>
<p>TV 500ml, dead space 150ml, RR 15/min, 350ml*15 = approx 5L/min -&gt; 7200L/day</p>
</blockquote>
</section><section id="ample-opportunity-for-sufficiently-small-particles-to-meet-the-interstitium" class="slide level2">
<h1>ample opportunity for sufficiently small particles to meet the interstitium</h1>
</section><section id="section-13" class="slide level2">
<h1></h1>
<ul>
<li>particles &gt; 2μm in diameter deposit in the larger airways</li>
<li>particles 1-2μm the smaller conducting airways</li>
<li>particles 0.1-1μm deposit in the alveolar-interstitial region</li>
</ul>
</section><section id="section-14" class="slide level2" data-background="images/particles.png">
<h1></h1>
</section><section id="section-15" class="slide level2">
<h1></h1>
<ul>
<li>the 0.1-1μm range includes paint pigments, metal dusts, and humidifier particles<br />
</li>
<li>responses to exposure can be divided e.g irritant/fibrotic/allergic/infectious/carcinogenic</li>
</ul>
</section><section id="work-related-ild" class="slide level2">
<h1>work-related ILD</h1>
</section><section id="ild-incidence-30100000-per-year" class="slide level2">
<h1>ILD incidence 30/100,000 per year</h1>
</section><section id="ild-prevalence-70100000" class="slide level2">
<h1>ILD prevalence 70/100,000</h1>
</section><section id="section-16" class="slide level2">
<h1></h1>
<ul>
<li>precise population prevalence and incidence of ILD hard to establish (classification problems, limitations of registry and insurance claim data).</li>
<li>best historic estimate of incidence 30/100,000 per year, prevalence 70/100,000. (10)</li>
<li>IIP most common, IPF 1/3rd of cases, more common in men.</li>
</ul>
</section><section id="of-ild-due-to-occupational-and-environmental-exposures" class="slide level2">
<h1>15-20% of ILD due to occupational and environmental exposures</h1>
</section><section id="aetiologies-are-many" class="slide level2">
<h1>aetiologies are many</h1>
</section><section id="section-17" class="slide level2">
<h1></h1>
<ul>
<li>common: include organic antigen, isocyanates, silica, cadium, diacetyl, asbestos</li>
<li>less common: cobalt, rare earths, plutonium</li>
</ul>
</section><section id="section-18" class="slide level2">
<h1></h1>
<figure>
<img src="images/hpcauses.jpeg" alt="Causes of hypersensitivity pneumonitis (19)" style="width:90.0%" /><figcaption>Causes of hypersensitivity pneumonitis (19)</figcaption>
</figure>
</section><section id="relationship-between-aetiolgic-agent-and-pathological-pattern-often-not-11" class="slide level2">
<h1>relationship between aetiolgic agent and pathological pattern often not 1:1</h1>
</section><section id="section-19" class="slide level2">
<h1></h1>
<figure>
<img src="images/Pathology.jpeg" alt="Pathologic Patterns and Causes (4)" style="width:90.0%" /><figcaption>Pathologic Patterns and Causes (4)</figcaption>
</figure>
</section><section id="clinical-features" class="slide level2">
<h1>Clinical features</h1>
<ul>
<li>Respiratory symptoms with an appropriate occupational or environmental exposure history</li>
<li>Host-factor (e.g adaptive immune response, systemic) vs exposure factor dominant presentations (local inflammatory response)</li>
<li>Investigations</li>
</ul>
</section><section id="attribution-frequently-non-trivial" class="slide level2">
<h1>Attribution frequently non-trivial</h1>
</section><section id="new-workplace-and-environmental-exposures-all-the-time" class="slide level2">
<h1>New workplace and environmental exposures all the time</h1>
</section><section id="section-20" class="slide level2">
<h1></h1>
<figure>
<img src="images/Attribution.jpg" alt="A hierarchy of attribution in occupational lung diseases (11)" style="width:90.0%" /><figcaption>A hierarchy of attribution in occupational lung diseases (11)</figcaption>
</figure>
</section></section>
<section><section id="recent-outbreaks" class="titleslide slide level1"><h1>Recent outbreaks</h1></section><section id="three-recent-outbreaks" class="slide level2">
<h1>Three recent outbreaks</h1>
</section><section id="section-21" class="slide level2">
<h1></h1>
<ol type="1">
<li>Ardystil</li>
<li>Indium tin oxide</li>
<li>South Korean lung</li>
</ol>
</section></section>
<section><section id="ardystil" class="titleslide slide level1"><h1>Ardystil</h1></section><section id="section-22" class="slide level2">
<h1></h1>
<ul>
<li>April 1992, two young women who worked at a textile factory were treated for interstitial lung disease and severe pulmonary insufficiency in Valencia.</li>
<li>Prompted investigation of all textile factories (A-H) using same spraying technique in the area</li>
<li>257 employees identified. 22 cases who met radiological and biopsy criteria for organising pneumonia. Six fatal cases.</li>
</ul>
</section><section id="section-23" class="slide level2">
<h1></h1>
<ul>
<li>Factory A had the highest risk of being a case (RR=24.3; 95% Cl=5.7-104.4), followed by Factory B (RR=11, 95% CI=11.9- 62.9) and only two out of 22 cases had never worked in factories A or B.</li>
<li>It was found that only in factories A and B had the presence of an airborne chemical by the trade name Acramin FWR that had recently been substituted with another related compound Acramin FWN.</li>
<li>Similar outbreak occurred later in the same year in Algeria. 5 cases among 12 textile workers air-spraying with &quot;products from spain&quot;, 1 fatality.(20)</li>
</ul>
</section><section id="section-24" class="slide level2">
<h1></h1>
<figure>
<img src="images/Ardystil1.jpeg" alt="Chest computed tomography image of Acramin (Ardystil) dye-associated organising pneumonia. Two patients with dyspnoea, reduced FEV1 and FVC. 2005. (1)" style="width:65.0%" /><figcaption>Chest computed tomography image of Acramin (Ardystil) dye-associated organising pneumonia. Two patients with dyspnoea, reduced FEV1 and FVC. 2005. (1)</figcaption>
</figure>
</section><section id="section-25" class="slide level2">
<h1></h1>
<figure>
<img src="images/Ardystil2.jpeg" alt="Cryptogenic organising pneumonia pattern in a lung biopsy of an Acramin (Ardystil) dye-exposed worker. (1)" style="width:65.0%" /><figcaption>Cryptogenic organising pneumonia pattern in a lung biopsy of an Acramin (Ardystil) dye-exposed worker. (1)</figcaption>
</figure>
</section><section id="section-26" class="slide level2">
<h1></h1>
<figure>
<img src="images/Acramin.png" alt="Chemical structure of Acramin FWN and Acramin FWR (12)" style="width:65.0%" /><figcaption>Chemical structure of Acramin FWN and Acramin FWR (12)</figcaption>
</figure>
</section><section id="section-27" class="slide level2">
<h1></h1>
<ul>
<li>Acramin FWR (tradname Ardystil) recently introduced as a replacement for Acramin FWN at the two factories where majority of cases had worked.</li>
<li>Animal studies confirmed respiratory toxicity.</li>
<li>Thought that highly negatively charged long-chain molecular structure of Acramin FWN contributes causes toxicity.</li>
</ul>
</section></section>
<section><section id="indium-tin-oxide" class="titleslide slide level1"><h1>Indium tin oxide</h1></section><section id="section-28" class="slide level2">
<h1></h1>
<ul>
<li>Indium tin oxide (ITO) is a sintered material used in making crystal displays for televisions and computers.</li>
<li>First case of ITO-associated interstitial pneumonitis was reported in 2003 in a 27-year-old Japanese worker (1)</li>
<li>Cases in Japan, US, and China confirm interstitial pneumonia similar to UIP, emphysema, PAP in indium workers. Two patients have died to date. (13)</li>
<li>Like Ardystil outbreak notable that cases are young, have severe respiratory disease, and colleagues who are also unwell.</li>
</ul>
</section><section id="section-29" class="slide level2">
<h1></h1>
<figure>
<img src="images/Indium1.jpg" alt="CT showing progression of disease over three years in a 28 year-old Indium worker. Ground glass opacities and interlobular thickening. (13)" style="width:65.0%" /><figcaption>CT showing progression of disease over three years in a 28 year-old Indium worker. Ground glass opacities and interlobular thickening. (13)</figcaption>
</figure>
</section><section id="section-30" class="slide level2">
<h1></h1>
<figure>
<img src="images/Indium2.jpg" alt="Range of histopatholgical features. A-C features of alveolar proteinois. D multinucleated giant cells, interstitial fibrosis, and brown particles composed predominantly of indium. (13)" style="width:65.0%" /><figcaption>Range of histopatholgical features. A-C features of alveolar proteinois. D multinucleated giant cells, interstitial fibrosis, and brown particles composed predominantly of indium. (13)</figcaption>
</figure>
</section></section>
<section><section id="south-korean-lung" class="titleslide slide level1"><h1>South Korean Lung</h1></section><section id="section-31" class="slide level2">
<h1></h1>
<figure>
<img src="images/Disinfectant.jpg" alt="&#39;&#39;A former South Korean executive of UK-based Reckitt Benckiser has received a seven-year prison sentence over a humidifier disinfectant linked to the death of around 100 people&#39;&#39;. BBC News website (accessed Jan 17 2017)" style="width:65.0%" /><figcaption>''A former South Korean executive of UK-based Reckitt Benckiser has received a seven-year prison sentence over a humidifier disinfectant linked to the death of around 100 people''. BBC News website (accessed Jan 17 2017)</figcaption>
</figure>
</section><section id="section-32" class="slide level2">
<h1></h1>
<ul>
<li>Household clustering (6 cases belonged to household clusters e.g had a partner or children also affected) was observed in a series of patients admitted to ICU with severe respiratory distress in the spring of 2011. (15)</li>
<li>Case series consisted of 17 patients (15 of which were female) with median age 35. Six were pregnant at presentation.</li>
<li>All presented with cough and dyspnoea. CT showed patchy consolidation followed by ground glass opacity and bronchiolocentric fibrotic changes.<br />
</li>
<li>Ten patients required mechanical ventilation. Four had lung transplants. Five of the six who did not have a lung transplant died.</li>
</ul>
</section><section id="section-33" class="slide level2">
<h1></h1>
<ul>
<li>An infective aetiology was initially suspected (because recent viral epidemics)</li>
<li>Epidemiological investigation (a hospital based case-control study) revealed that all patients had used humidifier disinfectant in their homes.</li>
<li>Cases defined as age 20-54, characteristic radiological appearance, no alternative diagnosis. Controls from O&amp;G, pulmonary, and allergy outpatients.</li>
<li>OR for HD use = 47.3 (95% CI 6.05 - 369.7, P &lt; 0.01)</li>
<li>It transpired that children had also been affected.</li>
</ul>
</section><section id="section-34" class="slide level2">
<h1></h1>
<ul>
<li>From 2006 epidemics of fatal lung injury in children were observed in Korea every spring (14).</li>
<li>Clinical characteristics of suspected cases between 2006-2011 were reviewed and association with humidifier disinfectant use made.</li>
<li>138 cases, average age 30.4 months. 80 children died.</li>
<li>Case-control (controls lobar pneumonia, asthma, or healthy) study found OR for HD use = 2.73 (95% CI; 1.41–5.90, P = 0.00)</li>
<li>No new cases following humidifier disinfectant ban in 2011.</li>
</ul>
</section><section id="section-35" class="slide level2">
<h1></h1>
<ul>
<li>Mechanism by which polyhexamethylene guanidine phosphate, poly(oxyalkylene guanidine) hydrochloride, chloromethylisothiazolinone/methylisothiazolinone (toxic materials within humidifier disinfectant) not yet known.</li>
<li>Avoidable? Writing about 'Humidifier fever' in Parke's third edition (1994) Pickering stated (use of humidifier biocides) &quot;should be discouraged because we have no knowledge of the effects of long-term exposure to this group of chemicals&quot;</li>
</ul>
</section><section id="section-36" class="slide level2">
<h1></h1>
<figure>
<img src="images/Disinfectant1.jpg" alt="3/52 from onset, patchy consolidation. B: 1/12, diffuse centrilobular ground-glass attenuation. C: 1 year, diffuse centrilobular fibrosis. D: 5 year old girl, severe disease, pneumomediastinum, pneumothorax, subcutaneous emphysema. (14)" style="width:65.0%" /><figcaption>3/52 from onset, patchy consolidation. B: 1/12, diffuse centrilobular ground-glass attenuation. C: 1 year, diffuse centrilobular fibrosis. D: 5 year old girl, severe disease, pneumomediastinum, pneumothorax, subcutaneous emphysema. (14)</figcaption>
</figure>
</section><section id="section-37" class="slide level2">
<h1></h1>
<figure>
<img src="images/Disinfectant2.jpg" alt="A: centrilobular interstitial thickening and fibrosis. B: Bronchiolocentroc destruction. C: Inflammatory infiltration and fibroblastic proliferation within alveolar septa and bronchioles. D: Loss of airspaces because of interstitial thickening and fibrosis. (14)" style="width:65.0%" /><figcaption>A: centrilobular interstitial thickening and fibrosis. B: Bronchiolocentroc destruction. C: Inflammatory infiltration and fibroblastic proliferation within alveolar septa and bronchioles. D: Loss of airspaces because of interstitial thickening and fibrosis. (14)</figcaption>
</figure>
</section><section id="section-38" class="slide level2">
<h1></h1>
</section></section>
<section><section id="mcqs" class="titleslide slide level1"><h1>MCQs</h1></section><section id="which-of-the-following-is-true-of-the-anatomy-of-the-lung" class="slide level2">
<h1>Which of the following is true of the anatomy of the lung?</h1>
</section><section id="section-39" class="slide level2">
<h1></h1>
<ol type="A">
<li>The blood gas-barrier is approximately 1/25th of the thickness of a sheet of paper.</li>
<li>It's estimated that the average adult has 300 million alveoli.</li>
<li>The volume of an alveoli is 14 times that of a grain of sand.</li>
<li>All of the above.</li>
</ol>
</section><section id="which-of-the-following-is-true-of-south-korean-lung" class="slide level2">
<h1>Which of the following is true of South Korean lung?</h1>
</section><section id="section-40" class="slide level2">
<h1></h1>
<ol type="A">
<li>It predominantly affected women and children.</li>
<li>Most adult patients did not require mechanical ventilation.</li>
<li>An infective aetiology was not initially suspected.</li>
<li>It has not resulted in legal proceedings.</li>
</ol>
</section><section id="which-of-the-following-is-true-of-indium-lung" class="slide level2">
<h1>Which of the following is true of Indium Lung?</h1>
</section><section id="section-41" class="slide level2">
<h1></h1>
<ol type="A">
<li>Cases have reported in China, Japan, and Korea.</li>
<li>It is characterized by a single distinct pathological appearance.</li>
<li>Disease onset typically occurs after age 60.</li>
<li>Several pathological appearances are associated with Indium Lung.</li>
</ol>
</section></section>
<section><section id="summary" class="titleslide slide level1"><h1>Summary</h1></section><section id="section-42" class="slide level2">
<h1></h1>
<ol type="1">
<li>Occupational and environmental exposures change over time giving risk to new disease outbreaks; the interstitium is vulnerable</li>
<li>Recent occupational and environmental interstitial lung disease outbreaks include Ardystil, Indium tin oxide, and South Korean lung</li>
<li>The relationship between exposures and pathological patterns is frequently not 1:1</li>
<li>Stay vigilant</li>
</ol>
</section></section>
<section><section id="questions" class="titleslide slide level1"><h1>Questions?</h1></section><section id="questions-and-contact" class="slide level2">
<h1>Questions and contact</h1>
<ul>
<li>carl.reynolds@imperial.ac.uk</li>
<li>www.carlreynolds.net</li>
</ul>
</section></section>
<section><section id="references" class="titleslide slide level1"><h1>References</h1></section><section id="section-43" class="slide level2">
<h1></h1>
<ol type="1">
<li>Cullinan, Paul, et al. &quot;Occupational lung diseases: from old and novel exposures to effective preventive strategies.&quot; The Lancet Respiratory Medicine (2017).</li>
<li>Reynolds CJ, Blanc PD. Organising Pneumonia and Other Uncommon Interstitial Disorders in Parkes’ Occupational Lung Disorders. CRC Press; 4th edition.</li>
<li>Litow, Francesca K., et al. &quot;Occupational interstitial lung diseases.&quot; Journal of occupational and environmental medicine 57.11 (2015): 1250-1254.</li>
<li>Glazer, Craig S. &quot;Occupation, avocation, and interstitial lung disease.&quot; Clinical Pulmonary Medicine 18.1 (2011): 20-28.</li>
<li>Wallis, Adam, and Katherine Spinks. &quot;The diagnosis and management of interstitial lung diseases.&quot; Bmj 350 (2015): h2072.</li>
</ol>
</section><section id="section-44" class="slide level2">
<h1></h1>
<ol start="6" type="1">
<li>Travis, William D., et al. &quot;An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.&quot; American journal of respiratory and critical care medicine 188.6 (2013): 733-748.</li>
<li>King TE. Approach to the adult with interstitial lung disease: Clinical evaluation. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2015.</li>
<li>West, John B. &quot;Role of the fragility of the pulmonary blood-gas barrier in the evolution of the pulmonary circulation.&quot; American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 304.3 (2013): R171-R176.</li>
</ol>
</section><section id="section-45" class="slide level2">
<h1></h1>
<ol start="9" type="1">
<li>McNulty, William, and Omar S. Usmani. &quot;Techniques of assessing small airways dysfunction.&quot; European clinical respiratory journal 1 (2013).</li>
<li>Coultas, David B., et al. &quot;The epidemiology of interstitial lung diseases.&quot; American journal of respiratory and critical care medicine 150.4 (1994): 967-972.</li>
<li>Tarlo, Susan, Paul Cullinan, and Benoit Nemery, eds. Occupational and environmental lung diseases: Diseases from Work, Home, Outdoor and Other Exposures. John Wiley &amp; Sons, 2011.</li>
<li>Hoet, P. H., et al. &quot;In vitro cytotoxicity of textile paint components linked to the&quot; Ardystil syndrome&quot;.&quot; Toxicological Sciences 52.2 (1999): 209-216.</li>
</ol>
</section><section id="section-46" class="slide level2">
<h1></h1>
<ol start="13" type="1">
<li>Cummings, Kristin J., et al. &quot;Indium lung disease.&quot; CHEST Journal 141.6 (2012): 1512-1521.</li>
<li>Kim, Kyung Won, et al. &quot;Humidifier disinfectant–associated children’s interstitial lung disease.&quot; American journal of respiratory and critical care medicine 189.1 (2014): 48-56.</li>
<li>Hong, Sang-Bum, et al. &quot;A cluster of lung injury associated with home humidifier use: clinical, radiological and pathological description of a new syndrome.&quot; Thorax (2014): thoraxjnl-2013.</li>
<li>http://ccnmtl.columbia.edu/projects/mmt/frontiers/web/chapter_2/8918.html</li>
<li>West, J. B., and O. Mathieu-Costello. &quot;Structure, strength, failure, and remodeling of the pulmonary blood-gas barrier.&quot; Annual review of physiology 61.1 (1999): 543-572.i</li>
</ol>
</section><section id="section-47" class="slide level2">
<h1></h1>
<ol start="18" type="1">
<li>West, John B. &quot;Thoughts on the pulmonary blood-gas barrier.&quot; American Journal of Physiology-Lung Cellular and Molecular Physiology 285.3 (2003): L501-L513.</li>
<li>Feary, Johanna R., and Joanna Szram. &quot;Occupational Hypersensitivity Pneumonitis: What Is the Evidence, When to Think of It, and What to Do.&quot; Clinical Pulmonary Medicine 23.1 (2016): 23-29.</li>
<li>Ould Kadi F, Mohammed-Brahim B, Fyad A, Lellou S,Nemery B. Outbreak of interstitial lung disease in textile dye sprayers in Algeria. Lancet 1994, 343,962-3</li>
<li>Lapple, C. E. &quot;Characteristics of particles and particle dispersoids.&quot; Stanford Research Institute Journal 5 (1961): 94.</li>
</ol>
</section></section>
    </div>
  </div>

  <script src="reveal.js/lib/js/head.min.js"></script>
  <script src="reveal.js/js/reveal.js"></script>

  <script>

      // Full list of configuration options available at:
      // https://github.com/hakimel/reveal.js#configuration
      Reveal.initialize({

        // Optional reveal.js plugins
        dependencies: [
          { src: 'reveal.js/lib/js/classList.js', condition: function() { return !document.body.classList; } },
          { src: 'reveal.js/plugin/zoom-js/zoom.js', async: true },
          { src: 'reveal.js/plugin/notes/notes.js', async: true }
        ]
      });
    </script>
    </body>
</html>
